Report Summary
This report covers antihypertensives, antidyslipidemics, and antithrombotics, which are the three leading categories of cardiovascular
therapies by sales. Current and forecast sales of leading established brands in these categories are provided. Growth brands, key
drug classes, and leading players through to 2017 are identified. Major pipeline products are profiled including estimated filing
year.Identify growth brands, key drug classes, and leading players through to 2017.Review sales forecasts to 2017 for leading
products, with analysis of key growth drivers and resistors across the seven major pharmaceutical markets.Evaluate the commercial
impact of recently completed and ongoing clinical trials.Assess the target populations, market potential, and forecast approval dates
of major pipeline products.Understand the present unmet needs, treatment guidelines, and the epidemiology of cardiovascular
disease.Antihypertensives are the largest drug category within the cardiovascular market by sales, but this category will undergo
significant value erosion by 2017, principally due to increasing generic competition in the angiotensin receptor blockers class, which
accounted for 70% of total antihypertensive sales in 2011The value of the antidyslipidemic class will fall to around $8.2bn in 2017,
partly due to the loss of exclusivity of Lipitor, previously the world's best-selling drug. The availability of generic atorvastatin will halt
Crestor sales growth up to loss of exclusivity.Novel oral anticoagulants are likely to be the fastest growing class of antithrombotics
over the forecast period, driven by sales of Boehringer Ingelheim's Pradaxa, Bayer's Xarelto, and Pfizer/Bristol-Myers Squibb's
Eliquis.How does the market outlook vary for the antihypertensives, antidyslipidemics, and antithrombotics categories up to
2017'What are the key growth brands'Which were the most important companies in the cardiovascular market in 2011'How will the
loss of exclusivity of leading brands shape the cardiovascular market, and can pipeline products compensate for these lost
sales'Which novel therapeutics offer significant potential for future growth'

The Cardiovascular Market Outlook to 2017 (From Issuu)

Page 1/3

Find Industry reports, Company profiles
and Market Statistics

ReportLinker

>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Â&#x192;
Â&#x192;

The Cardiovascular Market Outlook to 2017

This report covers antihypertensives, antidyslipidemics, and antithrombotics, which are the three leading categories of cardiovascular therapies by sales. Current and forecast sales of leading established brands in these categories are provided. Growth brands, key drug classes, and leading players through to 2017 are identified. Major pipeline products are profiled including estimated filing year.Identify growth brands, key drug classes, and leading players through to 2017.Review sales forecasts to 2017 for leading products, with analysis of key growth drivers and resistors across the seven major pharmaceutical markets.Evaluate the commercial impact of recently completed and ongoing clinical trials.Assess the target populations, market potential, and forecast approval dates of major pipeline products.Understand the present unmet needs, treatment guidelines, and the epidemiology of cardiovascular disease.Antihypertensives are the largest drug category within the cardiovascular market...